TriangleHEALTH PROFESSIONAL · SOURCE READING
Molecular-Targeted Therapies
Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors
Various therapies targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor receptor, and mammalian target of rapamycin (mTOR) are in development.[1,33] Therapeutic agents under investigation include the VEGF monoclonal antibody, bevacizumab and VEGF tyrosine kinase inhibitors, sunitinib, vatalanib, and sorafenib.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice